813 related articles for article (PubMed ID: 15212186)
1. [Clinical-pharmacological aspects to accelerate the development process from the preclinical to the clinical phase/1st communication: The contribution of clinical pharmacology].
Kuhlmann J
Arzneimittelforschung; 2004; 54(5):251-8. PubMed ID: 15212186
[TBL] [Abstract][Full Text] [Related]
2. [Clinical-pharmacological aspects to accelerate the development process from the preclinical to the clinical phase/2nd communication: promising strategies].
Kuhlmann J
Arzneimittelforschung; 2004; 54(6):307-13. PubMed ID: 15282874
[TBL] [Abstract][Full Text] [Related]
3. Alternative strategies in drug development: clinical pharmacological aspects.
Kuhlmann J
Int J Clin Pharmacol Ther; 1999 Dec; 37(12):575-83. PubMed ID: 10599949
[TBL] [Abstract][Full Text] [Related]
4. [Responsibilities of clinical pharmacology in the early phase of drug development].
Kuhlmann J
Med Klin (Munich); 2000 May; 95(1 Spec No):31-40. PubMed ID: 10851846
[TBL] [Abstract][Full Text] [Related]
5. Drug research: from the idea to the product.
Kuhlmann J
Int J Clin Pharmacol Ther; 1997 Dec; 35(12):541-52. PubMed ID: 9455711
[TBL] [Abstract][Full Text] [Related]
6. [Development of antituberculous drugs: current status and future prospects].
Tomioka H; Namba K
Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
[TBL] [Abstract][Full Text] [Related]
7. On setting the first dose in man: quantitating biotherapeutic drug-target binding through pharmacokinetic and pharmacodynamic models.
Lowe PJ; Tannenbaum S; Wu K; Lloyd P; Sims J
Basic Clin Pharmacol Toxicol; 2010 Mar; 106(3):195-209. PubMed ID: 20050847
[TBL] [Abstract][Full Text] [Related]
8. New ways of insulin delivery.
Heinemann L
Int J Clin Pract Suppl; 2011 Feb; (170):31-46. PubMed ID: 21323811
[TBL] [Abstract][Full Text] [Related]
9. [Research in the field of clinical pharmacology in the USSR].
Lakin KM; Makarov VA; Novikova NV
Farmakol Toksikol; 1982; 45(3):5-12. PubMed ID: 7047211
[TBL] [Abstract][Full Text] [Related]
10. Anticancer Drug Development: The Way Forward.
Connors T
Oncologist; 1996; 1(3):180-181. PubMed ID: 10387985
[TBL] [Abstract][Full Text] [Related]
11. A Historical View and Vision into the Future of the Field of Safety Pharmacology.
Bass AS; Hombo T; Kasai C; Kinter LB; Valentin JP
Handb Exp Pharmacol; 2015; 229():3-45. PubMed ID: 26091634
[TBL] [Abstract][Full Text] [Related]
12. Innovative approaches in drug development.
Chang M; Kenley S; Bull J; Chiu YY; Wang W; Wakeford C; McCarthy K
J Biopharm Stat; 2007; 17(5):775-89. PubMed ID: 17885865
[TBL] [Abstract][Full Text] [Related]
13. Strategies for dealing with metabolite elucidation in drug discovery and development.
Nassar AE; Talaat RE
Drug Discov Today; 2004 Apr; 9(7):317-27. PubMed ID: 15037231
[TBL] [Abstract][Full Text] [Related]
14. Applicability of bioanalysis of multiple analytes in drug discovery and development: review of select case studies including assay development considerations.
Srinivas NR
Biomed Chromatogr; 2006 May; 20(5):383-414. PubMed ID: 16307470
[TBL] [Abstract][Full Text] [Related]
15. PK/PD modelling and simulations: utility in drug development.
Rajman I
Drug Discov Today; 2008 Apr; 13(7-8):341-6. PubMed ID: 18405847
[TBL] [Abstract][Full Text] [Related]
16. Pharmacometrics at FDA: evolution and impact on decisions.
Powell JR; Gobburu JV
Clin Pharmacol Ther; 2007 Jul; 82(1):97-102. PubMed ID: 17538553
[TBL] [Abstract][Full Text] [Related]
17. Analysis of pharmacology data and the prediction of adverse drug reactions and off-target effects from chemical structure.
Bender A; Scheiber J; Glick M; Davies JW; Azzaoui K; Hamon J; Urban L; Whitebread S; Jenkins JL
ChemMedChem; 2007 Jun; 2(6):861-73. PubMed ID: 17477341
[TBL] [Abstract][Full Text] [Related]
18. Clinical pharmacokinetics: current requirements and future perspectives from a regulatory point of view.
Shah RR
Xenobiotica; 1993 Nov; 23(11):1159-93. PubMed ID: 8310705
[TBL] [Abstract][Full Text] [Related]
19. Toxicogenomics in drug discovery: from preclinical studies to clinical trials.
Yang Y; Blomme EA; Waring JF
Chem Biol Interact; 2004 Nov; 150(1):71-85. PubMed ID: 15522262
[TBL] [Abstract][Full Text] [Related]
20. A holistic strategy for characterizing the safety of metabolites through drug discovery and development.
Walker D; Brady J; Dalvie D; Davis J; Dowty M; Duncan JN; Nedderman A; Obach RS; Wright P
Chem Res Toxicol; 2009 Oct; 22(10):1653-62. PubMed ID: 19715349
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
